Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02970981
Recruitment Status : Active, not recruiting
First Posted : November 22, 2016
Results First Posted : March 11, 2020
Last Update Posted : January 25, 2022
Bristol-Myers Squibb
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Biological: Nivolumab Biological: Ipilimumab Phase 2

Detailed Description:
The investigators hypothesize that PD-1 blockade combined with CTLA-4 blockade using ipilimumab would have a favorable effect on the expansion and activity of human CD8+ T cytotoxic lymphocytes (CTLs) specific for tumor-associated antigens (ie, self antigens), which would translate into improved anti-cancer therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Trial of Ipilimumab With Nivolumab for Participants With Resected Stages IIIB/IIIC/ IV Melanoma
Actual Study Start Date : November 29, 2016
Actual Primary Completion Date : November 2018
Estimated Study Completion Date : February 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Nivolumab and Ipilimumab

Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)

Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks.

Biological: Nivolumab
Other Names:
  • Opdivo
  • NSC 748726

Biological: Ipilimumab
Other Names:
  • Yervoy
  • NSC 732442

Primary Outcome Measures :
  1. Number of Cases of Adverse Events Occurring During Study [ Time Frame: 12 weeks post-treatment start ]
    The adverse events are evaluated per Common Terminology Criteria for Adverse Events (CTCAE) V4.

Secondary Outcome Measures :
  1. Time to Relapse [ Time Frame: Up to 4 years ]
    Time to relapse will be reported (in months post-treatment) to assess the preliminary efficacy of the study drugs.

  2. Immune Response Assessment [ Time Frame: 12 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be at least 16 years of age;
  • Histologic diagnosis of resected Stages IIIB/IIIC/ IV melanoma, with no evidence of disease clinically and radiologically, and negative surgical margins. All melanomas regardless of primary site of disease will be allowed;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilized;
  • Prior treated brain or meningeal metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off immunosuppressive doses of systemic steroids (> 10 mg/day prednisone or equivalent) for at least 2 weeks before study drug administration;
  • Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration. Prior focal radiotherapy completed at least 2 weeks before study drug administration. No radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administration;
  • Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks before study drug administration;
  • Completed nitrosourea treatment at least 6 weeks before administration of any study drug;
  • Prior surgery that required general anesthesia must be completed at least 4 weeks before study drug administration. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration and subjects should be recovered;
  • Screening laboratory values must meet the following criteria:

white blood cells (WBCs) ≥ 2000 cells/μL

  • neutrophils ≥ 1500 cells/μL
  • platelets ≥ 100 x 103/μL
  • hemoglobin ≥ 9.0 g/dL
  • serum creatinine ≤ 2 mg/dL
  • AST ≤ 2.5 x upper limit of normal (ULN) without, and ≤ 5 x ULN with hepatic metastasis
  • ALT ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis
  • bilirubin ≤ 2 x ULN (except subjects with Gilbert's syndrome, who must have total bilirubin < 3.0 mg/dL)
  • Females of childbearing potential must:
  • use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab.
  • For female subjects to be considered as not having childbearing potential, they must meet 1 or more of the following criteria:
  • postmenopausal for at least 24 consecutive months;
  • surgically sterile (ie, have had a hysterectomy or bilateral oophorectomy);
  • females with irregular menstrual periods and/or on hormone replacement therapy must have a documented serum follicle stimulating hormone level > 35 mIU/mL;
  • Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception.
  • Subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained; and
  • Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

  • Subjects who fulfill any of the following conditions at Screening will not be eligible for admission into the study:
  • History of severe hypersensitivity reactions to other mAbs;
  • Prior non-melanoma malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast;
  • Subjects with any active autoimmune disease (Appendix 3) or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy;
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
  • Positive tests for hepatitis B virus surface antigen (HBV SAg) or hepatitis C virus ribonucleic acid (HCV RNA) indicating active or chronic infection;
  • Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-stimulation pathways);
  • Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids;
  • Underlying medical condition (eg, a condition associated with diarrhea) that, in the Investigator's opinion, would make the administration of either study drug or both study drugs hazardous to the subject or obscure the interpretation of toxicity determination or adverse events;
  • Pregnant or nursing; or
  • Current participation in another clinical study involving treatment with medications, radiation or surgery, or prior participation in this study.
  • Patients are excluded if they have active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for [lowest minimum is 4 weeks or more] after treatment is complete and within 28 days prior to the first dose of nivolumab administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.

As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen.

  • Allergies and Adverse Drug Reaction

    1. History of allergy to study drug components
    2. History of severe hypersensitivity reaction to any monoclonal antibody

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02970981

Layout table for location information
United States, New York
Laura and Isaac Perlmutter Cancer Center
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Jeffrey S Weber, MD, PhD NYU Perlmutter Cancer Center
  Study Documents (Full-Text)

Documents provided by NYU Langone Health:
Layout table for additonal information
Responsible Party: NYU Langone Health Identifier: NCT02970981    
Other Study ID Numbers: 16-00098
First Posted: November 22, 2016    Key Record Dates
Results First Posted: March 11, 2020
Last Update Posted: January 25, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by NYU Langone Health:
Monoclonal antibody
Programmed Death-1 (PD-1)
Programmed Death-Ligand 1 (PD-L1)
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action